Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02613650 · ClinicalTrials.gov registry record · Phase 1
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
A Phase 1 study of Advanced KRAS Positive Metastatic Colorectal Cancer, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02613650 is a Phase 1 study of Advanced KRAS Positive Metastatic Colorectal Cancer that has completed, run by University of Utah. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02613650, a Phase 1 study of Advanced KRAS Positive Metastatic Colorectal Cancer, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination
Conditions Studied
Interventions
- DRUG MEK162 and mFOLFIRI
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-08-19 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02613650
The ClinicalTrials.gov registry entry for NCT02613650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced KRAS Positive Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which MEK162 and mFOLFIRI is the first listed.
NCT02613650 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT02613650 about?
NCT02613650 is a clinical study titled "A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers". This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination
What is the current status of trial NCT02613650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-08-19. Estimated completion is 2022-12-21.
What conditions does trial NCT02613650 study?
This clinical trial studies the following conditions: Advanced KRAS Positive Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT02613650?
The interventions under investigation include: MEK162 and mFOLFIRI (DRUG).
Who is sponsoring clinical trial NCT02613650?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02613650 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.